Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir and Atazanavir Switch Study in HIV
NCT00751153Phase 4Unknown
- Sponsor
- Peter J. Ruane, M.D.
- Start
- Mar 2008
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of raltegravir and atazanavir in human immunodeficiency virus infection (HIV), sponsored by Peter J. Ruane, M.D. Primary endpoint: Proportion of patients with plasma HIV viral load < 400 copies/ml at 48 weeks. Status: unknown.
02
Drugs
raltegraviratazanavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00751153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00751153.